Gilead’s Kite unit plans to file its latest CAR-T therapy on the basis of a new study showing some impressive response rates in patients with relapsed or refractory mantle cell lymphoma.
Nearly half of patients with advanced lymphoma treated with Gilead/Kite’s CAR-T therapy Yescarta were alive after three years, according to new figures unveiled this weekend.
